Governance Neurocrine Biosciences, Inc.

NBIX

US64125C1099

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/07/2026 am IST			5-day change	1st Jan Change
170.88 ^USD	-0.39%		-5.36%	+20.48%

13/07	Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating	MT
10/07	Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing	MT

Executive Committee: Neurocrine Biosciences, Inc.

Manager

Positions heldSince

Kyle Gano

53 year

Chief Executive Officer	11/10/2024
President	11/10/2024

Sanjay Keswani

56 year

Chief Tech/Sci/R&D Officer

02/06/2025

Andrew Ratz

Chief Tech/Sci/R&D Officer

17/03/2026

Ingrid Delaet

60 year

General Counsel

01/01/2021

Jude Onyia

62 year

Chief Tech/Sci/R&D Officer

30/11/2021

Todd Tushla

Investor Relations Contact

01/09/2019

Matthew Abernethy

46 year

Director of Finance/CFO

01/11/2017

Julie Cooke

59 year

Human Resources Officer

01/09/2017

Darin Lippoldt

61 year

General Counsel	01/10/2014
Corporate Secretary	01/10/2014

Bill Wilson

Chief Operating Officer	01/03/2004
Chief Tech/Sci/R&D Officer	01/09/1996

Lewis Choi

Chief Tech/Sci/R&D Officer

09/06/2025

Composition of the Board of Directors: Neurocrine Biosciences, Inc.

Director

CommitteesSince

William Rastetter

78 year

Audit Committee	21/01/2015
Compensation Committee Chair	11/07/2019

Christine Poon

73 year

Executive Committee	01/09/2006
Finance Committee Chair
Governance Committee	06/02/2024
Compensation Committee Chair	16/11/2010
Finance Committee	05/05/2011
Audit Committee	12/02/2024
Nominating Committee	06/02/2024

Leslie Norwalk

60 year

Audit Committee	24/07/2019
Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair

Shalini Sharp

51 year

Compensation Committee	01/01/2024
Audit Committee Chair	01/01/2024
Governance Committee	16/01/2025
Nominating Committee	16/01/2025

George Morrow

74 year

Compensation Committee	01/11/2015
Governance Committee	01/11/2015
Nominating Committee	01/11/2015

Stephen Sherwin

77 year

Audit Committee	09/12/2011
Finance Committee	01/01/2010

Richard Pops

64 year

Compensation Committee Chair	01/04/1998
Finance Committee	01/09/2011

Johanna Mercier

56 year

Governance Committee	15/04/2021
Nominating Committee	15/04/2021

Kevin Gorman

68 year

Compensation Committee	14/04/2017
HR Committee	14/04/2017

Gary Lyons

75 year

Director/Board Member	01/02/1993
Independent Dir/Board Member	01/01/2008

Kyle Gano

53 year

Director/Board Member

11/10/2024

Latest Appointments: Neurocrine Biosciences, Inc.

18/03	Neurocrine Biosciences, Inc. Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer	CI
07/25/07	Neurocrine Biosciences appoints Mike Sibley as senior vice president, general manager of neuropsychiatry franchise	RE
07/25/07	Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise	CI
26/25/26	Innovent Biologics, Inc. Appoints Stephen A. Sherwin as an Independent Non-Executive Director and A Member of the Strategy Committee of the Board, Effective August 26, 2025	CI
10/25/10	Neurocrine Biosciences Names Lewis Choi as Chief Information Officer	MT
10/25/10	Neurocrine Biosciences Appoints Lewis Choi As Chief Information Officer	RE
10/25/10	Neurocrine Biosciences, Inc. Announces the Appointment of Lewis Choi as Chief Information Officer, Effective June 9, 2025	CI

More news

Former Officers and Directors: Neurocrine Biosciences, Inc.

Insider

Positions held

SinceUntil

Eiry Roberts

Chief Tech/Sci/R&D Officer

08/01/2018

02/06/2025

Malcolm Lloyd-Smith

General Counsel

01/09/2014

01/04/2023

Dimitri Grigoriadis

Chief Tech/Sci/R&D Officer	01/01/2013	01/01/2023
Corporate Officer/Principal	01/01/1993	01/01/2013

Brenda Van Vreeswyk

Human Resources Officer

01/02/2016

01/09/2022

Alfred Sandrock

Director/Board Member	03/09/2015	19/05/2020
Independent Dir/Board Member	03/09/2015	19/05/2020

Ebun Garner

Corporate Officer/Principal

01/03/2017

01/04/2019

Corinne Nevinny

Director/Board Member	01/06/2004	22/09/2018
Independent Dir/Board Member	01/06/2004	22/09/2018

Christopher Flint O'Brien

Chief Tech/Sci/R&D Officer

01/01/2005

08/01/2018

David-Alexandre Gros

Chief Operating Officer	06/01/2017	31/12/2017
Director of Finance/CFO	06/02/2017	31/12/2017
President	06/01/2017	31/12/2017

Joseph A. Mollica

Director/Board Member	24/02/2012	17/10/2017
Chairman	01/06/1997	24/02/2012
Independent Dir/Board Member	01/06/1997	17/10/2017

Daljit Singh Aurora

Corporate Officer/Principal

01/05/2015

01/07/2016

Ajay Madan

Corporate Officer/Principal

01/02/2013

01/07/2016

W. Thomas Mitchell

Director/Board Member	01/11/2002	20/05/2016
Independent Dir/Board Member	09/12/2011	20/05/2016

Yun Fei Zhu

Corporate Officer/Principal

01/01/1997

01/05/2009

Stephen Betz

Corporate Officer/Principal

01/06/2003

01/05/2009

Patricia Lady

Comptroller/Controller/Auditor	01/01/2007	01/01/2009
Director of Finance/CFO	01/01/2007	01/01/2009

Chrysa Mineo

Corporate Officer/Principal

01/01/1997

01/01/2009

Richard Ranieri

Chief Administrative Officer	01/02/2008	01/08/2008
Human Resources Officer	01/06/2005	01/08/2008

Carol A. Baum

Sales & Marketing

01/03/2003

01/02/2008

Zachary Hornby

Corporate Officer/Principal

01/06/2006

01/01/2008

R. Struthers

Director/Board Member	01/01/1998	01/01/2008
Corporate Officer/Principal	01/01/1998	01/01/2008

Stefan Proniuk

Corporate Officer/Principal

01/01/2008

Paul Hawran

Director of Finance/CFO	01/04/2007	01/04/2007
Founder	01/01/1993	01/04/2007

Adrian Adams

Director/Board Member

05/01/2005

14/02/2007

Niel C. Hoglen

Corporate Officer/Principal

01/01/2007

Wendell Wierenga

Chief Tech/Sci/R&D Officer

01/07/2004

01/12/2006

Henry Y. Pan

Chief Tech/Sci/R&D Officer

01/10/2001

02/06/2006

Robert J. Little

Corporate Officer/Principal

01/01/2003

01/01/2006

Yang Sai

Corporate Officer/Principal

01/01/2001

William Mccarthy

Corporate Officer/Principal

01/01/2005

01/01/2006

Lawrence Steinman

Director/Board Member	01/01/1997	01/01/2005
Founder	01/01/1997	01/01/2005

Thomas J. Joyce

Sales & Marketing

01/04/2002

01/01/2004

Michelle Martin

Comptroller/Controller/Auditor

01/01/2003

Stefen A. Boehme

Corporate Officer/Principal

01/01/1995

01/01/2003

Tim Coughlin

Director of Finance/CFO

01/09/2006

Barbara M. Finn

General Counsel

01/10/2000

Stephen Marcus

General Counsel

01/12/1997

01/09/1999

Errol de Souza

Director/Board Member	01/10/1992	01/08/1998
Chief Tech/Sci/R&D Officer	01/10/1992	01/08/1998
Founder	01/01/1992	01/08/1998

John W. Beck

Director of Finance/CFO

01/02/1994

01/04/1998

Margaret E. Valeur-Jensen

General Counsel	01/01/1998	-
Corporate Secretary	01/01/1998	-

Haig P. Bozigian

Corporate Officer/Principal

Howard Birndorf

Director/Board Member

01/01/1992

01/01/1997

Wylie W. Vale

Director/Board Member	01/09/1992	-
Founder	01/09/1992	-
Independent Dir/Board Member	01/09/1992	-

Brian Rosenberger

Sales & Marketing

Alan C. Foster

Corporate Officer/Principal

David Schnell

Director/Board Member

Derek Chalmers

Corporate Officer/Principal

Navjot Rai

Investor Relations Contact	-	-
Public Communications Contact	-	-

Paul J. Conlon

Chief Tech/Sci/R&D Officer

Gregory S. Naeve

Corporate Officer/Principal

Tilman Oltersdorf

Corporate Officer/Principal

Jason Zhang

Corporate Officer/Principal

Chen Chen

Corporate Officer/Principal

John Saunders

Chief Tech/Sci/R&D Officer

Scott Eliasof

Corporate Officer/Principal

Kevin B. Bacon

Corporate Officer/Principal

Pia Lindström

General Counsel

Jane Sorensen

Investor Relations Contact

Murray C. Maytom

Corporate Officer/Principal

Douglas Bakan

Corporate Officer/Principal

David Campbell

Corporate Officer/Principal

Jeffrey P. Whitten

Corporate Officer/Principal

Cynthia J. Thomas

Human Resources Officer

Margaret Bradbury

Corporate Officer/Principal

Age distribution of managers

Parity Men Women

Male	19
Female	5

Of which Executive Committee

Male	10
Female	1

Of which Directors

Male	7
Female	4

Revisions

Recommandations analystes

Évolution recommandations analystes 1 an

Évolution recommandations analystes 4 mois

Objectif analystes

Évolution objectif analystes 1 an

Évolution objectif analystes 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It is engaged in discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâ€™s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its first-in-class commercial portfolio includes INGREZZA (valbenazine) and CRENESSITY (crinecerfont). It also offers VYKAT XR (diazoxide choline) extended-release tablets, for the treatment of hyperphagia in adults and pediatric patients four years of age and older with Prader-Willi syndrome (PWS). Its pipeline includes direclidine / (M4 Agonist), osavampatorà¥¥ / (AMPA PAM) and others.

Employees

2,000

Sector

Pharmaceuticals

Calendar

31/07 - Earnings release - Q2 2026

More about the company